Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2004-02-27
2011-11-29
Burkhart, Michael (Department: 1633)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C424S093100, C514S04400A
Reexamination Certificate
active
08067567
ABSTRACT:
The present invention relates to a transcriptional regulatory sequence with enhanced tumor-specificity and strength and a recombinant vector comprising the transcriptional regulatory sequence. More particularly, the present invention relates to a transcriptional regulatory sequence comprising a human telomere reverse transcriptase (hTERT) promoter linked to a nucleotide sequence that comprises one or more c-Myc binding sites and/or one or more Sp1 binding sites, and a recombinant vector comprising a certain gene that is operably linked to the above transcriptional regulatory sequence.
REFERENCES:
patent: 7491525 (2009-02-01), Qian et al.
patent: 00/03104 (2000-08-01), None
patent: WO 03/006640 (2003-01-01), None
patent: WO 03/013555 (2003-02-01), None
pXC1 vector map, 1 page, printed from Microbix Biosystems website, Nov. 20, 2010.
pXC1 vector DNA sequence, 4 pages, printed from Microbix Biosystems website, Nov. 20, 2010.
Supplementary European Search Report, dated Jun. 29, 2006, for EPO Application No. EP04715577.
Kirch et al., “Tumor-specific activation of hTERT-derived promoters by tumor suppressive E1A-mutants involves recruitment of p300/CBP/HAT and suppression of HDAC-1 and defines a combined tumor targeting and suppression system” Oncogene, vol. 21, No. 52, Nov. 14, 2002, pp. 7991-8000.
Wick et al., “Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT)”, Gene: An International Journal on Genes and Genomes, Elsevier, Amsterdam, NL, vol. 232, May 17, 1999, pp. 97-106.
Greenberg et al., “Telemerase reverse transcriptase gene is a a direct target of c-Myc but is not functionally equivalent in cellular transformation” Oncogene, Basingstoke, Hants, GB, vol. 18, 1999, pp. 1219-1226.
Kim, E. et al., “Ad-mTERT-Δ19, a Conditional Replication-Competent Adenovirus Driven by the Human Telomerase Promoter, Selectively Replicates in and Elicits Cytopathic Effect in a Cancer Cell-Specific Manner” Human Gene Therapy, vol. 14, pp. 1415-1428, Oct. 10, 2003.
Kyo, S. et al., “Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT)” Nucleic Acids Research, vol. 28, No. 3, pp. 669-677, 2000.
Takakura, M. et al., “Cloning of Human Telomerase Catalytic Subunit (hTERT) Gene Promoter and Identification of Proximal Core Promoter Sequences Essential for Transcriptional Activation in Immortalized and Cancer Cells” Cancer Research, vol. 59, pp. 551-557, Feb. 1999.
Horikawa, I. et al., “Cloning and Characterization of the Promoter Region ofHuman Telomerase Reverse TranscriptaseGene” Cancer Research, vol. 59, pp. 826-830, Feb. 1999.
Kim, J. et al., “Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy”Cancer Gene Therapy, vol. 9, pp. 725-736, 2002.
Fisher, K.J. et al., “Recombinant Adenovirus Deleted of All Viral Genes for Gene Therapy of Cystic Fibrosis” Virology, vol. 217, pp. 11-22, 1996.
Kumar-Singh, R. et al., “Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells” Human Molecular Genetics, vol. 5, No. 7, pp. 913-921, 1996.
Abdallah, B. et al., “Non-viral gene transfer: Applications in developmental biology and gene therapy” Biology of the Cell, vol. 85, pp. 1-7, 1995.
Mizuguchi, H. et al., “Approaches for generating recombinant adenovirus vectors” Advanced Drug Reviews, vol. 52, pp. 165-176, 2001.
Kim Joo-Hang
Yang Jai-Myung
Yun Chae-Ok
Burkhart Michael
Holme Roberts & Owen LLP
Industry-Academic Cooperation Foundation - Yonsei University
LandOfFree
Modified tert promoter with enhanced tumor-specificity and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified tert promoter with enhanced tumor-specificity and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified tert promoter with enhanced tumor-specificity and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261981